Literature DB >> 31407000

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

M H Kulke, P Ruszniewski, E Van Cutsem, C Lombard-Bohas, J W Valle, W W De Herder, M Pavel, E Degtyarev, J C Brase, L Bubuteishvili-Pacaud, M Voi, R Salazar, I Borbath, N Fazio, D Smith, J Capdevila, R P Riechelmann, J C Yao.   

Abstract

Entities:  

Year:  2019        PMID： 31407000      PMCID： PMC8902961          DOI： 10.1093/annonc/mdz219

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis.

Authors:  Martin A Walter; Cédric Nesti; Marko Spanjol; Attila Kollár; Lukas Bütikofer; Viktoria L Gloy; Rebecca A Dumont; Christian A Seiler; Emanuel R Christ; Piotr Radojewski; Matthias Briel; Reto M Kaderli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-25

Review 2.  Advances in medical treatment for pancreatic neuroendocrine neoplasms.

Authors:  Yuan-Liang Li; Zi-Xuan Cheng; Fu-Huan Yu; Chao Tian; Huang-Ying Tan
Journal:  World J Gastroenterol       Date:  2022-05-28       Impact factor: 5.374

3.  Application of spectral CT combined with perfusion scan in diagnosis of pancreatic neuroendocrine tumors.

Authors:  Yamin Wan; Hui Hao; Yunjin Chen; Yifan Zhang; Qingmei Yue; Zhizhen Li
Journal:  Insights Imaging       Date:  2022-09-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.